164 related articles for article (PubMed ID: 28834410)
1. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer.
Zhu X; Li F; Ju X; Cao F; Cao Y; Fang F; Qing S; Shen Y; Jia Z; Zhang H
Cancer Med; 2017 Oct; 6(10):2263-2270. PubMed ID: 28834410
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Zhu X; Ju X; Cao Y; Shen Y; Cao F; Qing S; Fang F; Jia Z; Zhang H
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):101-110. PubMed ID: 30684663
[TBL] [Abstract][Full Text] [Related]
5. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
7. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
9. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy.
Ren S; Zhu X; Zhang A; Li D; Zuo C; Zhang H
Cancer Imaging; 2020 Mar; 20(1):22. PubMed ID: 32156306
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
14. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
15. [Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy].
Yu L; Li J; Gao M; Wang X; Bai H; Guan Y; Yuan Z
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):274-280. PubMed ID: 37183642
[TBL] [Abstract][Full Text] [Related]
16. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score).
Zhu X; Li F; Ju X; Shen Y; Cao Y; Cao F; Fang F; Qing S; Jia Z; Zhang H
Radiother Oncol; 2018 Nov; 129(2):313-318. PubMed ID: 30217337
[TBL] [Abstract][Full Text] [Related]
17. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma.
Iwai T; Yoshimura M; Ashida R; Goto Y; Kishi T; Itasaka S; Shibuya K; Kanai M; Masui T; Fukuda A; Isoda H; Hiraoka M; Mizowaki T
Radiat Oncol; 2020 Nov; 15(1):264. PubMed ID: 33187523
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]